Media Contact: Melody Udell
The ASCO Annual Meeting is more than a conference—it’s the place to be a part of something bigger. This is where groundbreaking science, innovation, and connection come together to shape the future of cancer care.
AMCP Nexus attracts more than 2,500 managed care decision-makers each fall. Attendees include individuals from health plans, PBMs, biopharmaceutical companies, consultants, and other leaders working within managed care pharmacy.
The FDA is attempting to shut down the black market for retatrutide, a pipeline treatment for obesity, type 2 diabetes and kidney and liver diseases that is still in final-phase testing. Investor’s Business Daily spoke to MMIT’s CCO Jayne Hornung about the black market, the drug’s potential for morbidly obese patients, and what’s likely to happen after FDA approval.
The success of the TrumpRx platform depends in large part on pharmacies’ willingness to accept lower reimbursement rates for drugs they’ve already purchased. MMIT’s Steve Callahan explained that as the program grows, pharmacies might reconsider their business model to ensure they can meet their own margins.
In an effort to reduce healthcare costs, the FDA would like many prescription medications to become over-the-counter products. MMIT’s Steve Callahan explains that while this move would theoretically improve patient access, patients would be responsible for the full cost of these treatments.
